Andera Partners co-leads a €67.5 million ($72 million) oversubscribed Series C round for cancer immunotherapy company Nouscom

Andera Partners co-leads a €67.5 million ($72 million) oversubscribed
Series C round for cancer immunotherapy company Nouscom Proceeds enable Nouscom to complete Phase 2 clinical trials with its cancer vaccine NOUS-209 Financing co-led by Andera, Bpifrance and M Ventures with support from new and existing investors Delegates from Andera, Bpifrance, and M Ventures have joined the Nouscom Board of Directors Paris, France – November 14, 2023 – Andera Partners, a leading European private equity player, today announces that it is co-leading a €67.5 million ($72 million) oversubscribed Series C financing for Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens. Alongside Andera, Bpifrance (through its InnoBio 2 fund) and M Ventures co-led the round, with participation from Revelation Partners, Indaco Venture Partners, Panakès Partners, X-Gen Ventures, and other undisclosed investors together with continued support from existing investors 5AM Ventures, EQT Life Sciences and Versant Ventures. Concurrent with the financing, representatives from Andera Partners, Bpifrance and M Ventures have joined the Nouscom Board of Directors. The proceeds will be used to continue advancing and expanding Nouscom’s wholly owned clinical pipeline to achieve multiple clinical value catalysts, including: Readout from Nouscom’s ongoing randomized Phase 2 clinical trial for NOUS-209, an off-the-shelf vaccine targeting 209 shared neoantigens, in combination with pembrolizumab for the treatment of Mismatch Repair/Microsatellite Instable (dMMR/MSI) Metastatic Colorectal Cancer (mCRC). Final readout from the ongoing Phase 1b study and advancement of NOUS-209 monotherapy in Lynch Syndrome (LS) carriers investigating the potential to intercept, prevent or delay cancer before it occurs. LS carriers have a genetic predisposition to and consequently higher risk of developing certain cancers. Promising initial results from this study were reported in a Late-breaking Abstract at the recent Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting – see press release here. Completion of a Phase 1b study evaluating NOUS-PEV, a personalized cancer immunotherapy, in combination with a checkpoint inhibitor in patients with advanced melanoma and entry into randomized Phase 2 trials in indications with high unmet medical needs. Dr. Marina Udier, Chief Executive Officer of Nouscom, said: “This oversubscribed financing, in what is a challenging environment for all biotech companies, is testament to the faith that new and existing investors place in Nouscom and our best-in-class technology. I am constantly inspired by the relentless drive our team exhibits on a daily basis to advancing our innovative medicines for the benefit of cancer patients. This financing will allow us to further accelerate development across our wholly owned clinical portfolio reporting multiple clinical trial readouts including from our ongoing randomized Phase 2 clinical trial with NOUS-209. These Phase 2 data, if positive, have the potential to position Nouscom’s neoantigen based cancer vaccines amongst the most thrilling developments in the field.” Dr. Goran Ando, Independent Chairman of Nouscom, said: “In conjunction with the financing, I am delighted to welcome all our new investors to the company and Sofia, Thibaut and Hakan from Andera, Bpifrance and M Ventures, respectively, to our Board of Directors. Together, with the experience of our existing Board Members, I look forward to their contributions as Nouscom navigates the next exciting steps in its journey.”

Dr. Sofia Ioannidou, Partner of Andera Partners, said: “We at Andera are delighted to support Marina and her team in their mission to advance the development of their innovative cancer treatments for patients. We believe that the robustness of the clinical results generated so far positions Nouscom as one of the leading biotech companies in the vibrant neoantigen cancer vaccine space. We look forward to supporting the company towards the further clinical validation of its platform.” About Nouscom

Nouscom is a clinical-stage immuno-oncology company developing next-generation, off-the-shelf and personalized cancer immunotherapies. Nouscom’s proprietary viral vector platform has the capacity to encode for large payloads of neoantigens or other immunomodulators and clinically demonstrated to safely and potently harness the power of the immune system. Nouscom is currently advancing the clinical development of its wholly owned programs: NOUS-209, an off-the-shelf cancer immunotherapy for the treatment of MSI solid tumors in combination with pembrolizumab in randomized Phase 2 trials.  In January 2023, Nouscom announced a clinical trial collaboration and pembrolizumab supply agreement with MSD (Merck & Co., Inc., Rahway, NJ, USA).
  NOUS-209, an off-the-shelf monotherapy in Lynch Syndrome carriers with the potential to ‘intercept cancer’ before it occurs. A Phase 1b is being conducted under a clinical trial collaboration and supply agreement signed in 2022 with the National Cancer Institute (NCI) and a randomized Phase 2 trial is expected to be initiated in 2024. 
  NOUS-PEV, a personalized cancer immunotherapy, is expected to enter randomized Phase 2 trials in indications with high unmet medical need in 2024.  Nouscom has also exclusively out-licensed VAC-85135, an off-the-shelf immunotherapy developed under a multi-project agreement, which is currently under evaluation in a Phase 1 trial for the treatment of Myeloproliferative Neoplasms sponsored by Janssen Research & Development and Bristol Myers Squibb. For more information on Nouscom, please visit the company’s website at www.nouscom.com or follow us on LinkedIn. ABOUT ANDERA PARTNERS

Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally. Its teams manage over €4 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion/Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra). Andera Partners’ mission is to work alongside companies and their managers to support them in achieving strong and sustainable growth. The quality of performance offered to our investors relies on a strong partnership between the entrepreneurs in our portfolio companies and our teams, based on shared values. Performance through collective engagement, the “Power of And”, constitutes Andera Partners’ DNA. Based in Paris, with offices in Antwerp, Milan and Munich, Andera Partners is wholly owned by its teams, which count nearly 110 professionals, of which 67 investment professionals. It is structured as a partnership and managed by a board of 12 partners. Andera’s 15-person life sciences team brings together extensive experience in the life sciences industry, private equity and venture capital. Active since 2000, the team has raised over €1.1 billion through its BioDiscovery family of funds and is currently investing from its new BioDiscovery 6 fund. Since inception, the BioDiscovery funds have invested in more than 75 European and U.S. biotech and medtech companies. For further information please visit: www.anderapartners.com MEDIA CONTACTS Nicolas DELSERT, Andera Partners: +33 6 22 67 71 17, n.delsert@anderapartners.com Raimund GABRIEL, MC Services: +49 89 210 228 0, andera@mc-services.eu Clément BENETREAU, Bien Commun Advisory: +33 6 76 14 02 02, c.benetreau@bcadvisory.fr